Literature DB >> 29414273

Acute Graft-versus-Host Disease.

.   

Abstract

Mesh：

Year:  2018        PMID： 29414273     DOI： 10.1056/NEJMc1716969

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-versus-host disease.

Authors:  Suze A Jansen; Edward E S Nieuwenhuis; Alan M Hanash; Caroline A Lindemans
Journal:  Mucosal Immunol       Date:  2022-06-02       Impact factor: 8.701

2.  Post Transplantation Bilirubin Nanoparticles Ameliorate Murine Graft Versus Host Disease via a Reduction of Systemic and Local Inflammation.

Authors:  Sumedha Pareek; Alexandra S Flegle; Drew Boagni; Jin Yong Kim; Dohyun Yoo; Abel Trujillo-Ocampo; Sung-Eun Lee; Mao Zhang; Sangyong Jon; Jin S Im
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

Review 3.  Targeting Regulatory T Cells by Addressing Tumor Necrosis Factor and Its Receptors in Allogeneic Hematopoietic Cell Transplantation and Cancer.

Authors:  Harald Wajant; Andreas Beilhack
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

4.  Mesenchymal stem cell exosome-derived miR-223 alleviates acute graft-versus-host disease via reducing the migration of donor T cells.

Authors:  Weijiang Liu; Na Zhou; Yuanlin Liu; Wei Zhang; Xue Li; Yang Wang; Rongxiu Zheng; Yi Zhang
Journal:  Stem Cell Res Ther       Date:  2021-02-26       Impact factor: 6.832

5.  Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites.

Authors:  David Michonneau; Eleonora Latis; Emmanuel Curis; Laetitia Dubouchet; Sivapriya Ramamoorthy; Brian Ingram; Régis Peffault de Latour; Marie Robin; Flore Sicre de Fontbrune; Sylvie Chevret; Lars Rogge; Gérard Socié
Journal:  Nat Commun       Date:  2019-12-13       Impact factor: 14.919

6.  A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy.

Authors:  Eva M Weissinger; Jochen Metzger; Michael Schleuning; Christoph Schmid; Diethelm Messinger; Gernot Beutel; Eva-Maria Wagner-Drouet; Johannes Schetelig; Herrad Baurmann; Andreas Rank; Friedrich Stolzl; Kerstin Schäfer-Eckart; Karin Westphal; Wolfgang Bethge; S von Harsdorf; Donald W Bunjes; Daniela Heidenreich; Stefan Klein; Ernst Holler; Hans H Kreipe; Danny Jonigk; Irina Türüchanow; Julia Raad; Armin Papkalla; Heiko von der Leyen; Lothar Hambach; Iyas Hamwi; Steve Ehrlich; Jurgen Krauter; Michael Stadler; Arnold Ganser
Journal:  Leukemia       Date:  2020-10-20       Impact factor: 11.528
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.